Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
- PMID: 40163799
- DOI: 10.1182/blood.2024028172
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Abstract
Potentially fatal non-immune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Comment in
-
A great mitigator of non-ICANS neurotoxicities?Blood. 2025 Jun 5;145(23):2682-2684. doi: 10.1182/blood.2025029233. Blood. 2025. PMID: 40471627 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources